Senores Pharmaceuticals Ltd
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
- Market Cap ₹ 4,449 Cr.
- Current Price ₹ 966
- High / Low ₹ 1,007 / 491
- Stock P/E 43.8
- Book Value ₹ 177
- Dividend Yield 0.00 %
- ROCE 11.4 %
- ROE 11.8 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Debtor days have improved from 177 to 114 days.
Cons
- Stock is trading at 5.43 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 21.7 days to 88.2 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 14 | 35 | 215 | 398 | 589 | |
| 12 | 23 | 173 | 309 | 431 | |
| Operating Profit | 2 | 13 | 42 | 90 | 157 |
| OPM % | 14% | 36% | 19% | 23% | 27% |
| 0 | 4 | 3 | 19 | 24 | |
| Interest | 1 | 2 | 9 | 22 | 22 |
| Depreciation | 1 | 2 | 10 | 17 | 27 |
| Profit before tax | 1 | 12 | 25 | 71 | 132 |
| Tax % | 13% | 32% | -31% | 17% | |
| 1 | 8 | 33 | 58 | 103 | |
| EPS in Rs | 1.01 | 8.59 | 10.31 | 12.72 | 22.05 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 204% |
| TTM: | 52% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 290% |
| TTM: | 79% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 80% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 15% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 31 | 46 | 46 |
| Reserves | 28 | 36 | 174 | 740 | 768 |
| 15 | 63 | 258 | 315 | 241 | |
| 8 | 23 | 160 | 126 | 233 | |
| Total Liabilities | 59 | 131 | 622 | 1,227 | 1,288 |
| 7 | 27 | 235 | 301 | 540 | |
| CWIP | 8 | 34 | 97 | 172 | 16 |
| Investments | 15 | 16 | 0 | 0 | 2 |
| 29 | 53 | 289 | 754 | 731 | |
| Total Assets | 59 | 131 | 622 | 1,227 | 1,288 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -10 | -1 | -26 | -46 | |
| -24 | -48 | -54 | -429 | |
| 36 | 46 | 87 | 573 | |
| Net Cash Flow | 2 | -3 | 8 | 98 |
| Free Cash Flow | -21 | -48 | -78 | -203 |
| CFO/OP | -526% | 3% | -56% | -41% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 506 | 228 | 191 | 114 |
| Inventory Days | 135 | 89 | 184 | 232 |
| Days Payable | 324 | 388 | 556 | 275 |
| Cash Conversion Cycle | 317 | -71 | -182 | 70 |
| Working Capital Days | 359 | -7 | -16 | 88 |
| ROCE % | 18% | 12% | 11% |
Insights
In beta| Mar 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|
| Annual Installed Capacity (API Manufacturing) MTPA |
|
||
| Approved ANDA Products/Strengths (Regulated Markets) Number |
|||
| Approved ANDAs (Regulated Markets) Number |
|||
| Approved Products (Emerging Markets) Number |
|||
| CDMO/CMO Commercialized Products Number |
|||
| Commercialized ANDAs (Regulated Markets) Number |
|||
| Pipeline Products/Applications Filed (Emerging Markets) Number |
|||
| Revenue Realization per Unit (Emerging Markets) INR |
|||
| Annual Installed Capacity (Atlanta OSD Facility) Million Units |
|||
| Annual Installed Capacity (Chhatral General Oral Dosage) Million Units |
|||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8 May - Senores Pharmaceuticals will hold Q4FY26 earnings call on May 14, 2026 at 5:00 P.M. IST.
-
Board Meeting Intimation for Considering And Approving The Audited Consolidated And Standalone Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 And To Transact Other Business Matters
8 May - Board meeting on May 14, 2026 to approve FY26 audited standalone and consolidated results.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
29 Apr - Senores Pharmaceuticals confirms it is not a Large Corporate; outstanding borrowing was Rs 54.07 crore as of March 31, 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Apr - Senores Pharmaceuticals Limited has informed regarding Certificate pursuant to Regulation 74(5) of SEBI (DP)Regulations,2018 for quarter ended March 31, 2026
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
3 Apr - Senores subsidiary SPI formed JV Amerisyn, LLC on April 2, 2026 for U.S. federal and defense supplies.
Concalls
-
Jan 2026Transcript PPT REC
-
Dec 2025TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT REC
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
May 2025TranscriptAI SummaryPPT
-
Jan 2025Transcript PPT REC
Business Overview:[1]
SPL is a global research-driven pharmaceutical company that develops and manufactures
pharmaceutical products for the Regulated Markets of the US, Canada, and the United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. The company develops and manufactures specialty, underpenetrated, and complex pharmaceutical products. It also manufactures critical care injectables and APIs.